Biological function and clinical relevance of chromogranin A and derived peptides

Endocrine Connections

Volumn 3, Issue 2, 2014, Pages

  Angela, Maria D'amico ^a   Ghinassi, Barbara ^a   Izzicupo, Pascal ^a   Manzoli, Lamberto ^a   Di Baldassarre, A ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CALCINEURIN; CATECHOLAMINE; CATESTATIN; CHROMACIN; CHROMOFUNGIN; CHROMOGRANIN A; CHROMOSTATIN; CYTOKINE; HISTAMINE; INOSITOL TRISPHOSPHATE; NICOTINIC RECEPTOR; PANCREASTATIN; PARASTATIN; PARATHYROID HORMONE; PROOPIOMELANOCORTIN; SCLEROPROTEIN; SECRETOGRANIN II; SECRETOGRANIN V; SERPININ; SIGNAL PEPTIDE; STATIN (PROTEIN); UNCLASSIFIED DRUG; VASCULOTROPIN; VASOSTATIN;

BIOGENESIS; CALCIUM HOMEOSTASIS; CALCIUM MOBILIZATION; CARBOHYDRATE METABOLISM; CARDIOVASCULAR FUNCTION; CATECHOLAMINE RELEASE; DNA SEQUENCE; ELECTRONIC MEDICAL RECORD; EXON; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; MULTIPLE ORGAN FAILURE; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS SECRETION; PANCREATIC NEUROENDOCRINE TUMOR; PATHOPHYSIOLOGY; PEER REVIEW; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS REGULATION; REGULATORY MECHANISM; REVIEW; TRANS GOLGI NETWORK; VASODILATATION;

EID: 85018664497     PISSN: None     EISSN: 20493614     Source Type: Journal    
DOI: 10.1530/EC-14-0027     Document Type: Review

References (88)

1. Bartolomucci A, Possenti R, Mahata SK, Fischer-Colbrie R, Loh YP & Salton SR. The extended granin family: structure, function, and biomedical implications. Endocrine Reviews 2011 32 755-797. (doi:10.1210/er.2010-0027)
2. Cohn DV, Zangerle R, Fischer-Colbrie R, Chu LL, Elting JJ, Hamilton JW &Winkler H. Similarity of secretory protein I from parathyroid gland to chromogranin A from adrenal medulla. PNAS 1982 79 6056-6059. (doi:10.1073/pnas.79.19.6056)
3. Fasciotto BH, Denny JC, Greeley GH & Cohn DV. Processing of chromogranin A in the parathyroid: generation of parastatin-related peptides. Peptides 2000 21 1389-1401. (doi:10.1016/S0196-9781(00)00283-7)
4. Bhargava G, Russell J & Sherwood LM. Phosphorylation of parathyroid secretory protein. PNAS 1983 80 878-881. (doi:10.1073/pnas.80.3.878)
5. Portela-Gomes GM, Grimelius L, Stridsberg M, Bresaola E, Viale G & Pelosi G. Expression of amino acid sequences of the chromogranin A molecule and synaptic vesicle protein 2 in neuroendocrine tumors of the lung. Virchows Archive 2005 446 604-612. (doi:10.1007/s00428-005-1222-6)
6. Stadinski BD, Delong T, Reisdorph N, Reisdorph R, Powell RL, Armstrong M, Piganelli JD, Barbour G, Bradley B, Crawford F et al. Chromogranin A is an autoantigen in type 1 diabetes. Nature Immunology 2010 11 225-231. (doi:10.1038/ni.1844)
7. Loh YP, Koshimizu H, Cawley NX & Tota B. Serpinins: role in granule biogenesis, inhibition of cell death and cardiac function. Current Medicinal Chemistry 2012 19 4086-4092. (doi:10.2174/ 092986712802429957)
8. Stettler H, Beuret N, Prescianotto-Baschong C, Fayard B, Taupenot L & Spiess M. Determinants for chromogranin A sorting into the regulated secretory pathway are also sufficient to generate granule-like structures in nonendocrine cells. Biochemical Journal 2009 418 81-91. (doi:10.1042/BJ20071382)
9. Hendy GN, Li T, Girard M, Feldstein RC, Mulay S, Desjardins R, Day R, Karaplis AC, Tremblay ML & Canaff L. Targeted ablation of the chromogranin A (ChgA) gene: normal neuroendocrine dense-core secretory granules and increased expression of other granins. Molecular Endocrinology 2006 20 1935-1947. (doi:10.1210/me.2005-0398)
10. Han L, Suda M, Tsuzuki K, Wang R, Ohe Y, Hirai H, Watanabe T, Takeuchi T & Hosaka M. A large form of secretogranin III functions as a sorting receptor for chromogranin A aggregates in PC12 cells. Molecular Endocrinology 2008 22 1935-1949. (doi:10.1210/me.2008-0006)
11. Yoo SH, Huh YH & Hur YS. Inositol 1,4,5-trisphosphate receptor in chromaffin secretory granules and its relation to chromogranins. Cellular and Molecular Neurobiology 2010 30 1155-1161. (doi:10.1007/ s10571-010-9564-2)
12. Mazza R, Imbrogno S & Tota B. The interplay between chromogranin A-derived peptides and cardiac natriuretic peptides in cardioprotection against catecholamine-evoked stress. Regulatory Peptides 2010 165 86-94. (doi:10.1016/j.regpep.2010.05.005)
13. Di Comite G & Morganti A. Chromogranin A: a novel factor acting at the cross road between the neuroendocrine and the cardiovascular systems. Journal of Hypertension 2011 29 409-414. (doi:10.1097/HJH. 0b013e328341a429)
14. Mahapatra NR, O'Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, Staite E, Wu H, Gu Y, Dalton N et al. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. Journal of Clinical Investigation 2005 115 1942-1952. (doi:10.1172/ JCI24354)
15. Wand GS, TakiyyuddinM, O'Connor DT & Levine MA. A proposed role for chromogranin A as a glucocorticoid-responsive autocrine inhibitor of proopiomelanocortin secretion. Endocrinology 1991 128 1345-1351. (doi:10.1210/endo-128-3-1345)
16. Ciesielski-Treska J, Ulrich G, Chasserot-Golaz S, Zwiller J, Revel MO, Aunis D & Bader MF. Mechanisms underlying neuronal death induced by chromogranin A-activated microglia. Journal of Biological Chemistry 2001 276 13113-13120. (doi:10.1074/jbc.M009711200)
17. Schrott-Fischer A, Bitsche M, Humpel C, Walcher C, Maier H, Jellinger K, Rabl W, Glueckert R & Marksteiner J. Chromogranin peptides in amyotrophic lateral sclerosis. Regulatory Peptides 2009 152 13-21. (doi:10.1016/j.regpep.2008.07.009)
18. Landén M, Davidsson P, Gottfries CG, Grenfeldt B, Stridsberg M & Blennow K. Reduction of the small synaptic vesicle protein synaptophysin but not the large dense core chromogranins in the left thalamus of subjects with schizophrenia. Biological Psychiatry 1999 46 1698-1702. (doi:10.1016/S0006-3223(99)00160-2)
19. Takahashi N, Ishihara R, Saito S, Maemo N, Aoyama N, Ji X, Miura H, IkedaM, Iwata N, Suzuki T et al. Association between chromograninAgene polymorphismand schizophrenia in the Japanese population. Schizophrenia Research 2006 83 179-183. (doi:10.1016/j.schres.2005.12.854)
20. Loh YP, Cheng Y, Mahata SK, Corti A & Tota B. Chromogranin A and derived peptides in health and disease. Journal of Molecular Neuroscience 2012 48 347-356. (doi:10.1007/s12031-012-9728-2)
21. Glattard E, Angelone T, Strub JM, Corti A, Aunis D, Tota B, Metz-Boutigue MH & Goumon Y. Characterization of natural vasostatin-containing peptides in rat heart. FEBS Journal 2006 273 3311-3321. (doi:10.1111/j.1742-4658.2006.05334.x)
22. Helle KB & Aunis D. A physiological role for the granins as prohormones for homeostatically important regulatory peptides? A working hypothesis for future research Advanced Experimental Medical Biology 2000 482 389-397. (doi:10.1007/0-306-46837-9_32)
23. Fornero S, Bassino E, Gallo MP, Ramella R, Levi R & Alloatti G. Endothelium dependent cardiovascular effects of the chromogranin A-derived peptides vasostatin-1 and catestatin. Current Medicinal Chemistry 2012 19 4059-4067. (doi:10.2174/092986712802429984)
24. Cerra MC, Gallo MP, Angelone T, Quintieri AM, Pulerà E, Filice E, Guèrold B, Shooshtarizadeh P, Levi R, Ramella R et al. The homologous rat chromogranin A1-64 (rCGA1-64) modulates myocardial and coronary function in rat heart to counteract adrenergic stimulation indirectly via endothelium-derived nitric oxide. FASEB Journal 2008 22 3992-4004. (doi:10.1096/fj.08-110239)
25. Belloni D, Scabini S, Foglieni C, Veschini L, Giazzon A, Colombo B, Fulgenzi A, Helle KB, Ferrero ME, Corti A et al. The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration. FASEB Journal 2007 21 3052-3062. (doi:10.1096/fj.06-6829com)
26. Imbrogno S, Angelone T, Corti A, Adamo C, Helle KB & Tota B. Influence of vasostatins, the chromogranin A-derived peptides, on the working heart of the eel (Anguilla anguilla): negative inotropy and mechanism of action. General and Comparative Endocrinology 2004 139 20-28. (doi:10.1016/j.ygcen.2004.07.008)
27. Tota B, Angelone T, Mazza R & CerraMC. The chromogranin A-derived vasostatins: new players in the endocrine heart. Current Medicinal Chemistry 2008 15 1444-1451. (doi:10.2174/092986708784567662)
28. Tota B, Cerra MC & Gattuso A. Catecholamines, cardiac natriuretic peptides and chromogranin A: evolution and physiopathology of a 'whip-brake' system of the endocrine heart. Journal of Experimental Biology 2010 213 3081-3103. (doi:10.1242/jeb.027391)
29. Zhang D, Shooshtarizadeh P, Laventie BJ, Colin DA, Chich JF, Vidic J, de Barry J, Chasserot-Golaz S, Delalande F, VanDorsselaer A et al. Two chromograninA-derived peptides induce calcium entry in human neutrophils by calmodulin-regulated calcium independent phospholipase A2. PLoS ONE 2009 4 e4501. (doi:10.1371/journal.pone.0004501)
30. Ratti S, Curnis F, Longhi R, Colombo B, Gasparri A, Magni F, Manera E, Metz-Boutigue MH & Corti A. Structure-activity relationships of chromogranin A in cell adhesion. Identification of an adhesion site for fibroblasts and smooth muscle cells. Journal of Biological Chemistry 2000 275 29257-29263. (doi:10.1074/jbc.M003796200)
31. Angeletti RH, D'Amico T & Russell J. Regulation of parathyroid secretion. Chromogranins, chemokines, andcalcium. Advanced ExperimentalMedical Biology 2000 482 217-223. (doi:10.1007/0-306-46837-9_17)
32. Eiden LE. Is chromogranin a prohormone? Nature 1987 325 301. (doi:10.1038/325301a0)
33. O'Connor DT, Cadman PE, Smiley C, Salem RM, Rao F, Smith J, Funk SD, Mahata SK, Mahata M, Wen G et al. Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. Journal of Clinical Endocrinology and Metabolism 2005 90 5414-5425. (doi:10.1210/jc.2005-0408)
34. Sánchez-Margalet V, González-Yanes C, Najib S & Santos-Álvarez J. Reprint of: metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin. Regulatory Peptides 2010 165 71-77. (doi:10.1016/j.regpep.2010.10.004)
35. Chen Y, Rao F, Wen G, Gayen JR, Zhang K, Vaingankar SM, Biswas N, Mahata M, Friese RS, Fung MM et al. Naturally occurring genetic variants in human chromogranin A (CHGA) associated with hypertension as well as hypertensive renal disease. Cellular and Molecular Neurobiology 2010 30 1395-1400. (doi:10.1007/s10571-010-9600-2)
36. O'Connor DT, Kailasam MT, Kennedy BP, ZieglerMG, Yanaihara N & Parmer RJ. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. Journal of Hypertension 2002 20 1335-1345. (doi:10.1097/00004872-200207000-00020)
37. Rao F, Wen G, Gayen JR, Das M, Vaingankar SM, Rana BK, Mahata M, Kennedy BP, Salem RM, Stridsberg M et al. Catecholamine releaseinhibitory peptide catestatin (chromograninA352-372): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 2007 115 2271-2281. (doi:10.1161/CIRCULATIONAHA.106.628859)
38. Fung MM, Salem RM, Mehtani P, Thomas B, Lu CF, Perez B, Rao F, Stridsberg M, Ziegler MG, Mahata SK et al. Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clinical and Experimental Hypertension 2010 32 278-287. (doi:10.3109/ 10641960903265246)
39. Friese RS, Gayen JR, Mahapatra NR, Schmid-Schönbein GW, O'Connor DT & Mahata SK. Global metabolic consequences of the chromogranin A-null model of hypertension: transcriptomic detection, pathway identification, and experimental verification. Physiological Genomics 2010 40 195-207. (doi:10.1152/physiolgenomics.00164.2009)
40. Angelone T, Quintieri AM, Brar BK, Limchaiyawat PT, Tota B, Mahata SK & Cerra MC. The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 2008 149 4780-4793. (doi:10.1210/en.2008-0318)
41. Biswas N, Gayen J, Mahata M, Su Y, Mahata SK & O'Connor DT. Novel peptide isomer strategy for stable inhibition of catecholamine release: application to hypertension. Hypertension 2012 60 1552-1559. (doi:10.1161/HYPERTENSIONAHA.112.202127)
42. 2+-calcineurin-NFAT signaling pathway. Biochemical and Biophysical Research Communications 2011 407 807-812. (doi:10.1016/j.bbrc.2011.03.104)
43. Theurl M, Schgoer W, Albrecht K, Jeschke J, Egger M, Beer AG, Vasiljevic D, Rong S, Wolf AM, Bahlmann FH et al. The neuropeptide catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor-dependent mechanism. Circulation Research 2010 107 1326-1335. (doi:10.1161/CIRCRESAHA.110.219493)
44. Kirchmair R, Gander R, Egger M, Hanley A, Silver M, Ritsch A, Murayama T, Kaneider N, Sturm W, Kearny M et al. The neuropeptide secretoneurin acts as a direct angiogenic cytokine in vitro and in vivo. Circulation 2004 109 777-783. (doi:10.1161/01.CIR.0000112574. 07422.C1)
45. Egger M, Beer AG, Theurl M, Schgoer W, Hotter B, Tatarczyk T, Vasiljevic D, Frauscher S, Marksteiner J, Patsch JR et al. Monocyte migration: a novel effect and signaling pathways of catestatin. European Journal of Pharmacology 2008 598 104-111. (doi:10.1016/j.ejphar.2008. 09.016)
46. Aung G, Niyonsaba F, Ushio H, Kajiwara N, Saito H, Ikeda S, Ogawa H & Okumura K. Catestatin, a neuroendocrine antimicrobial peptide, induces human mast cell migration, degranulation and production of cytokines and chemokines. Immunology 2011 132 527-539. (doi:10.1111/j.1365-2567.2010.03395.x)
47. Rangon CM, Haik S, Faucheux BA, Metz-Boutigue MH, Fierville F, Fuchs JP, Hauw JJ & Aunis D. Different chromogranin immunoreactivity between prion and a-b amyloid plaque. Neuroreport 2003 14 755-758. (doi:10.1097/00001756-200304150-00019)
48. Lechner T, Adlassnig C, Humpel C, Kaufmann WA, Maier H, Reinstadler-Kramer K, Hinterholzl J, Mahata SK, Jellinger KA & Marksteiner J. Chromogranin peptides in Alzheimer's disease. Experimental Gerontology 2004 39 101-113. (doi:10.1016/j.exger.2003.09.018)
49. Aslam R, Marban C, Corazzol C, Jehl F, Delalande F, Van Dorsselaer A, Prévost G, Haïkel Y, Taddei C, Schneider F & Metz-Boutigue MH. Cateslytin, a chromogranin A derived peptide is active against Staphylococcus aureus and resistant to degradation by its proteases. PLoS ONE 2013 8 e68993. (doi:10.1371/journal.pone.0068993)
50. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology 2001 69 89-95. (doi:10.1067/mcp.2001.113989)
51. Conlon JM. Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors. Regulatory Peptides 2010 165 5-11. (doi:10.1016/j.regpep.2009.11.013)
52. O'Toole D, Grossman A, Gross D, Delle-Fave G, Barkmanova J, O'Connor J, Pape UF & Plockinger U. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers. Neuroendocrinology 2009 90 194-202. (doi:10.1159/000225948)
53. Bartolomucci A, Pasinetti GM & Salton SR. Granins as diseasebiomarkers: translational potential for psychiatric and neurological disorders. Neuroscience 2010 170 289-297. (doi:10.1016/j.neuroscience. 2010.06.057)
54. Duque M, Modlin IM, Gupta A & Saif MW. Biomarkers in neuroendocrine tumors. Journal of Pancreas 2013 14 372-376. (doi:10.6092/1590-8577/1692)
55. Díaz Pérez JA & Currás Freixes M. Chromogranin A and neuroendocrine tumors. Endocrinologi{dotless}́a y Nutrición 2013 60 386-395. (doi:10.1016/ j.endonu.2012.10.003)
56. Massironi S, Conte D, Sciola V, Spampatti MP, Ciafardini C, Valenti L, Rossi RE & Peracchi M. Plasma chromograninA response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. American Journal of Gastroenterology 2010 105 2072-2078. (doi:10.1038/ajg.2010.154)
57. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. Journal of Clinical Oncology 2010 28 69-76. (doi:10.1200/ JCO.2009.24.2669)
58. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R & Yao JC. Flourouracil, doxorubicin, and streptozocin in the treatment of patients with advanced and metastatic pancreatic neuroendocrine carcinomas. Journal of Clinical Oncology 2004 22 4762-4771. (doi:10.1200/JCO.2004.04.024)
59. Belli SH, Oneto A, Aranda C, O'Connor JM, Domenichini E, Roca E, Méndez G, Bestani MC, Parma P, Giacomi N et al. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina. Acta Gastroenterologica Latinoamericana 2009 39 184-189.
60. Giovinazzo F, Schimmack S, Svejda B, Alaimo D, Pfragner R, Modlin I & Kidd M. Chromogranin a and its fragments as regulators of small intestinal neuroendocrine neoplasm proliferation. PLoS ONE 2013 8 e81111. (doi:10.1371/journal.pone.0081111)
61. Estensen ME, Hognestad A, Syversen U, Squire I, Ng L, Kjekshus J, Dickstein K & Omland T. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. American Heart Journal 2006 152 e1-e6. (doi:10.1016/j.ahj.2006.05.008)
62. Jansson AM, Røsjø H, Omland T, Karlsson T, Hartford M, Flyvbjerg A & Caidahl K. Prognostic value of circulating chromogranin A levels in acute coronary syndromes. European Heart Journal 2009 30 25-32. (doi:10.1093/eurheartj/ehn513)
63. Zhang D, Lavaux T, Sapin R, Lavigne T, Castelain V, Aunis D, Metz-Boutigue MH & Schneider F. Serum concentration of chromogranin A at admission: an early biomarker of severity in critically ill patients. Annals of Medicine 2009 41 38-44. (doi:10.1080/07853890802199791)
64. Di Comite G, Marinosci A, Di Matteo P, Manfredi A, Rovere-Querini P, Baldissera E, Aiello P, Corti A & Sabbadini MG. Neuroendocrine modulation induced by selective blockade of TNF-a in rheumatoid arthritis. Annals of the New York Academy of Sciences 2006 1069 428-437. (doi:10.1196/annals.1351.041)
65. Kamboh MI. Molecular genetics of late-onset Alzheimer's disease. Annals of Human Genetics 2004 68 381-404. (doi:10.1046/j.1529-8817. 2004.00110.x)
66. Simonsen AH, McGuire J, Podust VN, Hagnelius NO, Nilsson TK, Kapaki E, Vassilopoulos D & Waldemar G. A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dementia and Geriatric Cognitive Disorders 2007 24 434-440. (doi:10.1159/000110576)
67. Stoop MP, Dekker LJ, Titulaer MK, Burgers PC, Sillevis Smitt PA, Luider TM & Hintzen RQ. Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics 2008 8 1576-1585. (doi:10.1002/pmic.200700446)
68. Syversen U, Ramstad H, Gamme K, Qvigstad G, Falkmer S & Waldum HL. Clinical significance of elevated serum chromogranin A levels. Scandinavian Journal of Gasteroenterology 2004 10 969-973. (doi:10.1080/00365520410003362)
69. Peracchi M, Gebbia C, Basilisco G, Quatrini M, Tarantino C, Vescarelli C, Massironi S & Conte D. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. European Journal of Endocrinology 2005 152 443-448. (doi:10.1530/eje.1.01862)
70. O'Connor DT, Pandlan MR, Carlton E, Cervenka JH & Hslao RJ. Rapid radioimmunoassay of circulating chromogranin a: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clinical Chemistry 1989 35 1631-1637.
71. Nobels FR, Kwekkeboom DJ, Coopmans W, Hoekstra R, De Herder WW, Bouillon R & Lamberts SW. A comparison between the diagnostic value of the measurement of gonadotropins, a-subunits and chromogranin A and their response to TRH in clinically non-functioning, a-subunit secreting and gonadotroph pituitary adenoma. Journal of Clinical Endocrinology and Metabolism 1993 77 784-789. (doi:10.1210/jcem.77. 3.7690365)
72. Saruta J, Tsukinoki K, Sasaguri K, Ishii H, Yasuda M, Osamura YR, Watanabe Y & Sato S. Expression and localization of chromogranin A gene and protein in human submandibular gland. Cells, Tissues, Organs 2005 180 237-244. (doi:10.1159/000088939)
73. Allgrove JE, Gomes E, Hough J & GleesonM. Effects of exercise intensity on salivary antimicrobial proteins and markers of stress in active men. Journal of Sports Sciences 2008 26 653-661. (doi:10.1080/ 02640410701716790)
74. Kawada S, Fukusaki C, Ohtani M & Kobayashi K. Effects of hyperoxic inhalation on psychological stress-induced salivary biomarkers. Biomedical Research 2009 30 245-249. (doi:10.2220/biomedres.30.245)
75. Rai B & Kaur J. Salivary stress markers and psychological stress in simulated microgravity: 21 days in 68 head-down tilt. Journal of Oral Science 2011 53 103-107. (doi:10.2334/josnusd.53.103)
76. Fukui M, Hinode D, Yokoyama M, Yoshioka M, Kataoka K & Ito H. Levels of salivary stress markers in patients with anxiety about halitosis. Archives of Oral Biology 2010 55 842-847. (doi:10.1016/j.archoralbio. 2010.07.014)
77. Wagner J, Cik M, Marth E, Santner BI, Gallasch E, Lackner A & Raggam RB. Feasibility of testing three salivary stress biomarkers in relation to naturalistic traffic noise exposure. International Journal of Hygiene and Environmental Health 2010 213 153-155. (doi:10.1016/ j.ijheh.2009.08.004)
78. Katsuura S, Kamezaki Y, Yamagishi N, Kuwano Y, Nishida K, Masuda K, Tanahashi T, Kawai T, Arisawa K & Rokutan K. Circulating vascular endothelial growth factor is independently and negatively associated with trait anxiety and depressive mood in healthy Japanese university students. International Journal of Psychophysiology 2011 81 38-43. (doi:10.1016/j.ijpsycho.2011.04.004)
79. Tsubouchi H, Nakai Y, Toda M, Morimoto K, Chang YS, Ushioda N, Kaku S, Nakamura T, Kimura T & Shimoya K. Change of salivary stress marker concentrations during pregnancy: maternal depressive status suppress changes of those levels. Journal of Obstetrics and Gynaecology Research 2011 37 1004-1009. (doi:10.1111/j.1447-0756.2010.01473.x)
80. Matsumoto T, Asakura H & Hayashi T. Increased salivary chromogranin A in women with severe negative mood states in the premenstrual phase. Journal of Psychosomatic Obstetrics and Gynaecology 2012 33 120-128. (doi:10.3109/0167482X.2012.697498)
81. Bocanegra OL, Diaz MM, Teixeira RR, Soares SS & Espindola FS. Determination of the lactate threshold by means of salivary biomarkers: chromogranin A as novel marker of exercise intensity. European Journal of Applied Physiology 2012 112 3195-3203. (doi:10.1007/s00421-011-2294-4)
82. Gallina S, Di Mauro M, D'Amico MA, D'Angelo E, Sablone A, Di Fonso A, Bascelli A, Izzicupo P & Di Baldassarre A. Salivary chromogranin A, but not a-amylase, correlates with cardiovascular parameters during high-intensity exercise. Clinical Endocrinology 2011 75 747-752. (doi:10.1111/j.1365-2265.2011.04143.x)
83. Robazza C, Gallina S, D'Amico MA, Izzicupo P, Bascelli A, Di Fonso A, Mazzaufo C, Capobianco A & Di Baldassarre A. Relationship between biological markers and psychological states in elite basketball players across a competitive season. Psychology of Sport and Exercise 2012 13 509-517. (doi:10.1016/j.psychsport.2012.02.011)
84. Den R, Toda M, Nagasawa S, Kitamura K & Morimoto K. Circadian rhythm of human salivary chromogranin A. Biomedical Research 2007 28 57-60. (doi:10.2220/biomedres.28.57)
85. Dag E, Aydin S, Ozkan Y, Erman F, Dagli AF & Gurger M. Alteration in chromogranin A, obestatin and total ghrelin levels of saliva and serum in epilepsy cases. Peptides 2010 31 932-937. (doi:10.1016/j.peptides. 2010.02.009)
86. Stefanescu AM, Schipor S, Paun D, Dumitrache C & Badiu C. Plasma versus salivary chromogranin a as selective markers in pheochromocytoma diagnosis. Acta Endocrinologica 2011 VII 153-162. (doi:10.4183/aeb.2011.153)
87. Kanamaru Y, Kikukawa A & Shimamura K. Salivary chromogranin-A as a marker of psychological stress during a cognitive test battery in humans. Stress 2006 9 127-131. (doi:10.1080/14769670600909594)
88. Mahata SK, Mahata M, Fung MM & O'Connor DT. Catestatin: a multifunctional peptide from chromogranin A. Regulatory Peptides 2010 162 33-43. (doi:10.1016/j.regpep.2010.01.006)